FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
Verrucous lichen planus: a rare presentation of a common condition
2389PDF: 869HTML: 1110 -
06 | PERIOCULAR “ULCUS RODENS-LIKE” SQUAMOUS CELL CARCINOMA TREATED WITH CEMIPLIMAB: A CASE REPORT A. Zordan1, M. Fino1, N. Di Meo1, I. Zalaudek1, C. Defferrari2, S. Sola3, C. Massone4 | 1Department of Dermatology and Venereology, University of Trieste, Maggiore Hospital, Trieste, Italy; 2Department of Oncology, Galliera Hospital, Genoa, Italy; 3Department of Pathology, Galliera Hospital, Genoa, Italy; 4Department of Dermatology, Galliera Hospital, Genoa, Italy
105PDF: 37 -
36 | MORBIHAN DISEASE IN A MAURITIAN PATIENT: A CASE REPORT AND REVIEW OF THE ASIAN LITERATURE G. Hoxhallari1|4, R. Bortone2, A. R. Meduri2, B. Tirone2, F. Drago3, C. Foti2, D. Bonamonte2, M. Bellino2, G. Ciccarese1 | 1Unit of Dermatology, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy; 2Section of Dermatology and Venereology, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari “Aldo Moro”, Bari, Italy; 3Casa di Cura Villa Montallegro, Genova, Italy; 4Department of Dermatology and Venereology, Mother Teresa University Hospital Center, Tirana, Albania
105PDF: 41 -
23 | Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: an international retrospective study Maria Chiara Sergi*1, Teresa Amaral*2, Piotr Rutkowski*3, Marie-Lena Rasch2, Naima Benannoune4, Patricio Serra5, Maria Grazia Vitale6, Diana Giannarelli7, Ana Maria Arance8, Eva Munoz Couselo9, Bart Neyns10, Iris Dirven11, Marco Tucci12, Michele Guida13, Francesco Spagnolo14, Ernesto Rossi15, Paola Queirolo16, Pietro Quaglino17, Roberta Depenni18, Joanna Placzke3, Anna Maria Di Giacomo19, Michele Del Vecchio20, Alice Indini20, Ines Pires da Silva21, Alexander M. Menzies22, Angela Hong23, Paul Lorigan5, Caroline Robert24, Georgina V. Long22, Paolo A. Ascierto6, Mario Mandalà25 | 1Unit of Medical Oncology, "Mons. A.R. Dimiccoli" Hospital, Asl BT, Barletta, Italy; 2Skin Cancer Clinical Trials Center, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany. 3Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland. 4Gustave Roussy Cancer Campus, Villejuif, France. 5The University of Manchester, Manchester, UK. 6Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, I.N.T. IRCCS Fondazione "G. Pascale" Napoli, Naples, Italy; 7Epidemiology and Biostatistics, Fondazione Policlinico Universitario, A. Gemelli IRCCS, Rome, Italy; 8Hospital Clínic Barcelona and IDIBAPS, Barcelona, Spain; 9Department of medical oncology. Vall d"Hebron Hospital, Barcelona, Spain & Vall d’Hebron Institute of oncology, VHIO. Barcelona, Spain; 10Department of Medical Oncology, UZ Brussel, Brussels, Belgium. 11Department of medical oncology, Vrije Universiteit Brussel, VUB, Universitair Ziekenhuis Brussel, Brussels, Belgium; 12Medical Oncology Unit, University of Bari Aldo Moro, Policlinico Hospital of Bari, 70124 Bari, Italy. 13Rare Tumors and Melanoma Unit, IRCCS Istituto dei Tumori "Giovanni Paolo II," Bari, Italy. 14IRCCS Ospedale Policlinico San Martino, Skin Cancer Unit, Genova, Italy; 15Medical Oncology, Fondazione Policlinico Universitario, A. Gemelli IRCCS, Rome, Italy; 16IEO European Institute of Oncology, IRCCS, Milan, Italy. 17Department of Dermatology, University of Turin, Turin, Italy. 18University of Modena and Reggio Emilia, Department of Oncology, Hematology, Modena, Emilia-Romagna, Italy; 19Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy. 20Unit of Melanoma Medical Oncology, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 21Melanoma Institute Australia, University of Sydney, and Blacktown Hospital, Sydney, New South Wales, Australia; 22Melanoma Institute Australia, University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia; 23Faculty of Medicine and Health, Sydney Medical School, The University of Sydney, Australia; Department of Radiation Oncology, Chris O'Brien Lifehouse, Camperdown, NSW, Australia; 24Gustave Roussy and Paris-Saclay University, Villejuif, France; 25Unit of Medical Oncology, University of Perugia, Perugia, Italy. § on behalf of the Italian Melanoma Intergroup - IMI.
417 -
-
The interaction of inflammatory cells in granuloma faciale
2151PDF: 652HTML: 348 -
10 | LEBRIKIZUMAB PROVIDES CLINICALLY MEANINGFUL RESPONSE IN FACE AND HANDS IN ADULTS AND ADOLESCENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: ADHOPE 1 STUDY L. Stingeni1, C. Vestergaard2, J. Seneschal3|4, S. Weidinger5, A. Wollenberg6|7|8, A. Irvine9, H. Agell10, J. Valls Bancells10, V. Sapena10, D. Thaçi7 | 1Dermatology Section, Department of Medicine and Surgery, University of Perugia, Italy; 2Department of Dermatology and Venerology, Aarhus University Hospital, Aarhus, Denmark; 3Department of Dermatology, University of Bordeaux, Bordeaux, France; 4Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, Hospital Saint-André, Bordeaux, France; 5Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany; 6University Medical Center of Augsburg, Augsburg, Germany; 7Institute and Comprehensive Center for Inflammatory Medicine at the University of Lübeck, Lübeck, Germany; 8Department of Dermatology and Allergology, LMU Hospital, Munich, Germany; 9Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland; 10Almirall S.A., Barcelona, Spain
210PDF: 135 -
29 | The extracellular vesicle potential for the early detection of resistance to immunotherapy in melanoma patients Cristina Catoni1, Cristina Poggiana1, Alessandro Francesco Piazza1, Jacopo Pigozzo2, Luisa Piccin2, Chiara Menin1, Stefania Pellegrini1, Valentina Salizzato2, Paolo Del Fiore4, Simone Mocellin3|4, Vanna Chiarion-Sileni2, Valentina Guarneri2|3, Antonio Rosato1|3, Maria Chiara Scaini1 | 1Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua; 2Medical Oncology 2, Veneto Institute of Oncology, IOV-IRCCS, Padua; 3Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua; 4Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
375 -
Dermatitis artefacta: a challenging diagnosis
1010PDF: 295HTML: 38 -
24 | IXEKIZUMAB WITH OR WITHOUT TIRZEPATIDE IN ADULTS WITH PSORIASIS AND OVERWEIGHT OR OBESITY: THE TOGETHER-PSO PHASE 3B RANDOMIZED CLINICAL TRIAL E. Filippi1, M. Lebwohl2, A. Blauvelt3, C. Kartman4, C. Leatherwood4, K. Gordon5, N. Sattar6, L. Puig7, J. Merola8, K. Siu4, R. Wang4, L. Sun4, A. Leung9, N. Somani4, M. Rueda4, A. Cardoso4, M. Genovese4, A. Armstrong10, B. Strober11 | 1Eli Lilly Italy S.p.A, Sesto Fiorentino, Italy; 2Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 3Blauvelt Consulting, LLC, Annapolis, MD, USA; 4Eli Lilly and Company, Indianapolis, IN, USA; 5Department of Dermatology, Medical College of Wisconsin, Milwaukee, WI, USA; 6School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK; 7Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona School of Medicine, Barcelona, Spain; 8Department of Dermatology and Department of Medicine, Division of Rheumatology, UT Southwestern Medical Center and O’Donnell School of Public Health, Dallas, TX, USA; 9Syneos Health, Morrisville, NC, USA; 10Division of Dermatology, University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA, USA; 11Department of Dermatology, Yale University School of Medicine, New Haven, CT, Central Connecticut Dermatology Research, Cromwell, CT, USA
121PDF: 44 -
36 | Neoadjuvant strategy for locally advanced conjunctival melanoma: a single-center approach to eye preservation F. Rifaldi1|2, M. Angi3, L. Giuseppe1, F. Lanza3, A. Spagnoletti1, J. Sergenti3, A. Indini1, E. Mastrogiuseppe3, M. Del Vecchio1, L. Di Guardo1 | 1Melanoma Medical Oncology Unit, Department of Medical Oncology ed Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; 2Fondazione IRCCS Policlinico San Matteo, Pavia; 3Ocular Oncology Service, Department of Surgical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
522 -
32 | BEYOND AREA REDUCTION: PULSED DYE LASER TREATMENT OF BASAL CELL CARCINOMA IN A PRELIMINARY REAL-WORLD COHORT G. Frattin1|2, A. Bolzon1|2, E. Pezzolo1, L. Germi1, L. Gnesotto1, A. Corrà1, G. Mioso1, Z. Fratton1, L. Schiesari1 | 1UOC Dermatologia, Ospedale San Bortolo, Vicenza, Italy; 2Università degli Studi di Padova, Clinica Dermatologica, Italy
109PDF: 41 -
Transient cutaneous hypomelanosis after cryoanesthesia
1026PDF: 469HTML: 34 -
Measuring the impact of pruritus in patients with epidermolysis bullosa: evaluation with an itch-specific instrument
1224PDF: 403APPENDIX S1: 220HTML: 20
